Related Experiment Videos
Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency
T Evald1, A Dirksen, S Keittelmann
1Department of Pulmonary Medicine P, Bispebjerg Hospital, Copenhagen, Denmark.
Lung
|January 1, 1990
Summary
Individuals with severe alpha-1-antitrypsin (AAT) deficiency experience lung function decline. Smokers and non-smokers are at risk for pulmonary emphysema, with disease onset potentially later in non-smokers.
Area of Science:
- Pulmonology
- Genetics
- Internal Medicine
Background:
- Alpha-1-antitrypsin (AAT) deficiency (phenotype PiZ) is a genetic disorder predisposing individuals to severe lung disease.
- Pulmonary emphysema is a significant complication, necessitating understanding of disease progression in affected individuals.
Purpose of the Study:
- To investigate the annual decline in pulmonary function in patients with severe AAT deficiency.
- To assess the influence of smoking status on the rate of lung function decline and disease onset.
Main Methods:
- Longitudinal follow-up of 65 patients with severe AAT deficiency (PiZ phenotype) over a median of four years.
- Regular spirometry measurements, with pulmonary function data adjusted for sex, age, and height.
- Analysis of FEV1 decline rates in relation to smoking status (smokers, ex-smokers, never-smokers).
Main Results:
- The median annual decline in FEV1 was 1.9% predicted/year, largely independent of age and initial pulmonary function.
- While not statistically significant, ex-smokers and smokers showed a tendency towards faster FEV1 decline (1.7% and 3.8% predicted/year) compared to never-smokers (3.7% predicted/year).
- Smokers and ex-smokers presented with lower FEV1 at diagnosis and were younger than never-smokers.
Conclusions:
- Both smokers and non-smokers with severe AAT deficiency are at risk of developing pulmonary emphysema.
- The progression rate of emphysema appears similar regardless of smoking status, but disease onset may be delayed in non-smokers.